Feb. 19 at 3:01 PM
Eupraxia Pharmaceuticals Inc announced the pricing of its previously disclosed public offering. The clinical-stage biotech is selling 6,428,574 common shares at
$7.00 per share and pre-funded warrants to purchase up to 1,428,571 common shares at
$6.99999 per warrant, for expected gross proceeds of approximately
$55 million before underwriting discounts and expenses.
The company also granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms. The offering is expected to close on February 20, 2026, subject to customary closing conditions.
Cantor Fitzgerald and LifeSci Capital are acting as joint book-running managers, with Bloom Burton and Craig-Hallum serving as co-managers.
$EPRX